Regeneron Pharmaceuticals ( REGN ) has now announced the pricing of an underwritten offering of $1.250 billion aggregate principal amount of senior unsecured notes due 2030 and $750 million aggregate principal amount of senior unsecured notes due 2050. The 2030 notes will bear interest at 1.750% per annum and will mature on September 15, 2030. The 2050 notes will bear interest at 2.800% per annum and will mature on September 15, 2050. According to the statement, the issuance of the notes is expected to close on or around August 12, 2020, subject to customary closing conditions.